$AGIO
AGIOS PHARMACEUTICALS, INC. Stock $agio

$agio Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000143922221000073 Filed on November 03, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q4
Revenue	$0.00	$0.00	$44.05M
YoY Change	-100.0%	-100.0%	24.28%
Cost Of Revenue		$0.00	$960.0K
YoY Change		-100.0%	231.03%
Gross Profit		$0.00	$43.09M
YoY Change		-100.0%	22.59%
Gross Profit Margin			97.83%
Selling, General & Admin	$31.53M	$27.15M	$39.78M
YoY Change	-20.74%	-22.07%	14.21%
% of Gross Profit			92.32%
Research & Development	$73.30M	$64.00M	$95.74M
YoY Change	-23.44%	23.21%	-9.89%
% of Gross Profit			222.19%
Depreciation & Amortization	$2.202M	$2.209M	$2.700M
YoY Change	-18.44%	-7.96%	35.0%
% of Gross Profit			6.27%
Operating Expenses	$104.8M	$64.00M	$135.5M
YoY Change	-22.65%	23.21%	-3.94%
Operating Profit		-$91.15M	-$92.43M
YoY Change		13.53%	-12.74%
Interest Expense	$332.0K	$256.0K	$790.0K
YoY Change	-57.97%	-77.14%	-77.93%
% of Operating Profit
Other Income/Expense, Net	$3.268M	$4.641M	-$6.010M
YoY Change	-154.38%
Pretax Income	-$98.58M	-$84.26M	-$84.54M
YoY Change	16.61%	6.42%	-17.4%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$94.63M	-$88.77M	-$97.66M
YoY Change	-3.11%	-10.32%	-4.58%
Net Earnings / Revenue			-221.73%
Basic Earnings Per Share	-$1.74	-$1.56	-$1.41
Diluted Earnings Per Share	-$1.74	-$1.56	-$1.41
COMMON SHARES
Basic Shares Outstanding	54.31M shares	57.05M shares	69.26M shares
Diluted Shares Outstanding		57.05M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.020B	$1.266B	$572.9M
YoY Change	78.04%	109.08%	1.43%
Cash & Equivalents	$203.1M	$400.2M	$127.4M
Short-Term Investments	$816.9M	$865.8M	$445.5M
Other Short-Term Assets	$39.84M	$32.24M	$23.70M
YoY Change	68.08%	11.55%	-2.07%
Inventory	$0.00		$14.70M
Prepaid Expenses
Receivables			$21.30M
Other Receivables	$4.378M	$6.990M	$0.00
Total Short-Term Assets	$1.064B	$1.305B	$636.7M
YoY Change	67.15%	95.08%	4.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$28.92M	$25.34M	$30.82M
YoY Change	-6.14%	-24.34%	-2.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$266.4M	$130.1M	$97.60M
YoY Change	172.93%	11.33%	-36.17%
Other Assets	$2.900M	$2.900M	$0.00
YoY Change		114.81%
Total Long-Term Assets	$373.5M	$236.2M	$216.3M
YoY Change	72.7%	-1.32%	-22.49%
TOTAL ASSETS
Total Short-Term Assets	$1.064B	$1.305B	$636.7M
Total Long-Term Assets	$373.5M	$236.2M	$216.3M
Total Assets	$1.438B	$1.541B	$853.0M
YoY Change	68.56%	69.68%	-4.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.70M	$10.31M	$17.72M
YoY Change	-5.78%	-19.8%	-19.05%
Accrued Expenses	$31.97M	$29.23M	$30.80M
YoY Change	3.79%	-41.21%	-42.04%
Deferred Revenue	$0.00		$0.00
YoY Change			-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$331.0K	$412.0K	$300.0K
YoY Change	10.33%	37.33%	0.0%
Total Short-Term Liabilities	$59.83M	$57.90M	$94.39M
YoY Change	-36.62%	-17.02%	1.62%
LONG-TERM LIABILITIES
Long-Term Debt	$276.0K	$0.00	$300.0K
YoY Change	-8.0%	-100.0%	-57.14%
Other Long-Term Liabilities	$276.0K	$88.84M	$358.7M
YoY Change	-99.92%	-75.17%	128.91%
Total Long-Term Liabilities	$276.0K	$88.84M	$359.0M
YoY Change	-99.92%	-75.2%	128.08%
TOTAL LIABILITIES
Total Short-Term Liabilities	$59.83M	$57.90M	$94.39M
Total Long-Term Liabilities	$276.0K	$88.84M	$359.0M
Total Liabilities	$145.8M	$146.7M	$453.5M
YoY Change	-67.86%	-65.72%	81.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$238.8M	-$144.1M	-$1.843B
YoY Change	-87.05%	-91.74%	21.59%
Common Stock	$2.334B	$2.323B	$2.243B
YoY Change	4.08%	4.35%	4.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$802.5M	$783.4M	$0.00
YoY Change
Treasury Stock Shares	16.22M shares	15.80M shares	0.000 shares
Shareholders Equity	$1.292B	$1.395B	$399.5M
YoY Change
Total Liabilities & Shareholders Equity	$1.438B	$1.541B	$853.0M
YoY Change	68.56%	69.68%	-4.24%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q4
OPERATING ACTIVITIES
Net Income	-$94.63M	-$88.77M	-$97.66M
YoY Change	-3.11%	-10.32%	-4.58%
Depreciation, Depletion And Amortization	$2.202M	$2.209M	$2.700M
YoY Change	-18.44%	-7.96%	35.0%
Cash From Operating Activities	-$84.09M	-$85.18M	-$49.40M
YoY Change	70.23%	24.9%	-47.22%
INVESTING ACTIVITIES
Capital Expenditures	-$4.502M	$22.00K	-$1.000M
YoY Change	350.2%	-100.42%	-85.51%
Acquisitions
YoY Change
Other Investing Activities	-$89.92M	-$232.8M	$72.50M
YoY Change	-224.02%	92.2%	-140.73%
Cash From Investing Activities	-$94.42M	-$232.7M	$71.30M
YoY Change	-232.42%	84.41%	-138.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-18.59M	-251.0M	600.0K
YoY Change	-3197.67%	-7481.91%	-99.78%
NET CHANGE
Cash From Operating Activities	-84.09M	-85.18M	-49.40M
Cash From Investing Activities	-94.42M	-232.7M	71.30M
Cash From Financing Activities	-18.59M	-251.0M	600.0K
Net Change In Cash	-197.1M	-568.9M	22.50M
YoY Change	-975.99%	197.85%	-2912.5%
FREE CASH FLOW
Cash From Operating Activities	-$84.09M	-$85.18M	-$49.40M
Capital Expenditures	-$4.502M	$22.00K	-$1.000M
Free Cash Flow	-$79.59M	-$85.21M	-$48.40M
YoY Change	64.44%	35.25%	-44.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001439222
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69293920	shares
CY2020Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	47859000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	1305285000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	636677000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36014
	dei	Entity Registrant Name EntityRegistrantName	AGIOS PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-0662915
	dei	Entity Address Address Line1 EntityAddressAddressLine1	88 Sidney Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	649-8600
	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.001 per share
	dei	Trading Symbol TradingSymbol	AGIO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54308474	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	400224000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	127436000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	865833000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	445493000	USD
CY2021Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	6990000	USD
CY2020Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	32238000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15889000	USD
CY2021Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Noncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	130139000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Noncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	97608000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	77532000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	84661000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25342000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30815000	USD
CY2021Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	300000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	590000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2900000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2021Q3	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	0	USD
CY2020Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	2601000	USD
CY2021Q3	us-gaap	Assets Assets	1541498000	USD
CY2020Q4	us-gaap	Assets Assets	852952000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	10308000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17724000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	29234000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30801000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9883000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7093000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	146736000	USD
CY2021Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	412000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	317000	USD
CY2021Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	8059000	USD
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	USD
CY2021Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2020Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	38459000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	57896000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	94394000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	88840000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	97458000	USD
CY2021Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	331000	USD
CY2021Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	0	USD
CY2020Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	261269000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	453452000	USD
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70515336	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54715184	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69293920	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	71000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	69000	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2322460000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2242801000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-198000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	105000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-144133000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1843475000	USD
CY2021Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	15800152	shares
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2021Q3	us-gaap	Treasury Stock Value TreasuryStockValue	783438000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	1394762000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	399500000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1541498000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	852952000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	64000000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51943000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	183674000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	161388000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27152000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28347000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	89917000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	89196000	USD
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	91152000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	80290000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	273591000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	250584000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-91152000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-80290000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-273591000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-250584000	USD
CY2021Q3	agio	Contingent Gain On Disposition Of Business Recognized ContingentGainOnDispositionOfBusinessRecognized	1996000	USD
CY2020Q3	agio	Contingent Gain On Disposition Of Business Recognized ContingentGainOnDispositionOfBusinessRecognized	0	USD
	agio	Contingent Gain On Disposition Of Business Recognized ContingentGainOnDispositionOfBusinessRecognized	3996000	USD
	agio	Contingent Gain On Disposition Of Business Recognized ContingentGainOnDispositionOfBusinessRecognized	0	USD
CY2021Q3	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	256000	USD
CY2020Q3	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	1115000	USD
	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	504000	USD
	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	5820000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4641000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11165000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-84259000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-79175000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-257926000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-244764000	USD
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-4507000	USD
CY2020Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-19804000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	1957268000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	15051000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-88766000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-98979000	USD
	us-gaap	Net Income Loss NetIncomeLoss	1699342000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-229713000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.48
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.48
CY2020Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.15
CY2020Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.15
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-4.13
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-4.13
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-3.55
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-3.55
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.08
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.08
CY2020Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.29
CY2020Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.29
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	31.31
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	31.31
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.22
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.22
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.56
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.56
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.43
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.43
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	27.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	27.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.33
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57048175	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57048175	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69144061	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69144061	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62503087	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62503087	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68905853	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68905853	shares
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-88766000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-98979000	USD
	us-gaap	Net Income Loss NetIncomeLoss	1699342000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-229713000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-54000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-973000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-303000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	461000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-88820000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-99952000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1699039000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-229252000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	399500000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7347000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14854000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-108000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	1874325000	USD
CY2021Q1	agio	Stockholders Equity Disposition Of Business StockholdersEquityDispositionOfBusiness	-712000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	2296630000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	25673000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14885000	USD
CY2021Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	529047000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-141000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-86217000	USD
CY2021Q2	agio	Stockholders Equity Disposition Of Business StockholdersEquityDispositionOfBusiness	-33000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	1721816000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4009000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12148000	USD
CY2021Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	254391000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-54000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-88766000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	1394762000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	640528000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5465000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15670000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-128000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-40256000	USD
CY2020Q1	agio	Stockholders Equity Disposition Of Business StockholdersEquityDispositionOfBusiness	-4020000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	625299000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1652000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17614000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1562000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-90478000	USD
CY2020Q2	agio	Stockholders Equity Disposition Of Business StockholdersEquityDispositionOfBusiness	-2816000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	558465000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3532000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14977000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-973000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-98979000	USD
CY2020Q3	agio	Stockholders Equity Disposition Of Business StockholdersEquityDispositionOfBusiness	-3430000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	480452000	USD
	us-gaap	Net Income Loss NetIncomeLoss	1699342000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-229713000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	1957268000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	15051000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-257926000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-244764000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	7038000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	7202000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	41887000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	48261000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-5326000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1521000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-9000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	agio	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	7129000	USD
	agio	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	6691000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	6990000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	19249000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1231000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3337000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3056000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2667000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1317000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-5315000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6112000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-234095000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-192805000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-89132000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-48557000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-323227000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-241362000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	951411000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	430624000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	492911000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	448866000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1239000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13544000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-459739000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	4698000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	1802936000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-348000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1343197000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4350000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	773000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	250000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	783438000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	37029000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	10649000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-747182000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	10399000	USD
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	250537000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-747182000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	260936000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	272788000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23924000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	127436000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80931000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	400224000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104855000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	486000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	18660000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	19507000	USD
CY2021Q3	agio	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	44385000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	119876000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	21153000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	98723000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.057
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.057
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y4M24D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y2M12D
CY2021Q3	agio	Lessee Operating Sublease Area Of Premises Subleased LesseeOperatingSubleaseAreaOfPremisesSubleased	12995	sqft
CY2021Q3	us-gaap	Sublease Income SubleaseIncome	100000	USD
	us-gaap	Sublease Income SubleaseIncome	100000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	276000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	1118000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	1152000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	1186000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	3732000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	185000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	511000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in prior periods have been reclassified to reflect the impact of the discontinued operations treatment of the oncology business in order to conform to the current period presentation.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and any variant strains of the virus and the actions taken to contain the pandemic or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div>
CY2021Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	1400000000	USD
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-4507000	USD
CY2020Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-19804000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	1957268000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	15051000	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2020Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2021Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	996162000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	32000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	222000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	995972000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	542996000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	321000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	216000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	543101000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	116	security
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	87	security
CY2021Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	0	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	692500000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	299000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	0	security
CY2021Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	0	security
CY2021Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P6Y
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	13599000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20345000	USD
CY2021Q3	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	7435000	USD
CY2020Q4	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	5444000	USD
CY2021Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3246000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2897000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4954000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2115000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	29234000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30801000	USD
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	3800000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	3800000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	11400000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	11400000	USD
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	3600000	USD
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	3500000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	10800000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	10900000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2425000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	16773000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	18126000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6143046	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	58.46
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12148000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14977000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1036439	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	55.95
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	744663	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	45.22
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1402231	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	62.20
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5032591	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	58.86
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3392192	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	61.02
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5032591	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	58.86
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	41887000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	48261000	USD
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12148000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14977000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	41887000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	48261000	USD
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6121543	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7588924	shares
CY2021Q3	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	3900000	USD
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	16800000	USD
CY2020Q3	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0	USD
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	8900000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD

Files In Submission

Name	View Source	Status
0001439222-21-000073-index-headers.html	Edgar Link	pending
0001439222-21-000073-index.html	Edgar Link	pending
0001439222-21-000073.txt	Edgar Link	pending
0001439222-21-000073-xbrl.zip	Edgar Link	pending
agio-20210930.htm	Edgar Link	pending
agio-20210930.xsd	Edgar Link	pending
agio-20210930_cal.xml	Edgar Link	unprocessable
agio-20210930_def.xml	Edgar Link	unprocessable
agio-20210930_htm.xml	Edgar Link	completed
agio-20210930_lab.xml	Edgar Link	unprocessable
agio-20210930_pre.xml	Edgar Link	unprocessable
exhibit1019-30x21bowdenchr.htm	Edgar Link	pending
exhibit1029-30x2138sidneys.htm	Edgar Link	pending
exhibit31-1x09x30x21.htm	Edgar Link	pending
exhibit31-2x09x30x21.htm	Edgar Link	pending
exhibit32-1x09x30x21.htm	Edgar Link	pending
exhibit32-2x09x30x21.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AGIO
AGIOS PHARMACEUTICALS, INC. Stock $agio

2021 Q4 Form 10-Q Financial Statement

#000143922221000073 Filed on November 03, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO AGIOS PHARMACEUTICALS, INC. Stock $agio

2021 Q4 Form 10-Q Financial Statement

#000143922221000073 Filed on November 03, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO
AGIOS PHARMACEUTICALS, INC. Stock $agio